2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. Carbonic Anhydrase
  5. Carbonic Anhydrase Inhibitor

Carbonic Anhydrase Inhibitor

Carbonic Anhydrase Isoform Comparison

Carbonic Anhydrase Inhibitors (237):

Cat. No. Product Name Effect Purity
  • HY-13650
    Indisulam
    		Inhibitor 99.80%
    Indisulam (E 7070) is a carbonic anhydrase inhibitor with anticancer activity. Indisulam (E 7070) is a sulfonamide agent that targets the G1 phase of the cell cycle. Indisulam (E 7070) causes a blockade in the G1/S transition through inhibition of the activation of both CDK2 and cyclin E. Indisulam (E 7070) targets splicing by inducing RBM39 degradation via recruitment to DCAF15.
  • HY-B0782
    Acetazolamide
    		Inhibitor 99.89%
    Acetazolamide is a carbonic anhydrase (CA) IX inhibitor with an IC50 of 30 nM for hCA IX. Acetazolamide has diuretic, antihypertensive and anti-gonococcal activities.
  • HY-13513
    U-104
    		Inhibitor 99.95%
    U-104 (SLC-0111) is a potent carbonic anhydrase (CA) inhibitor for CA IX and CA XII with Ki values of 45.1 nM and 4.5 nM, respectively. U-104 shows a significant delay in tumor growth in mice model.
  • HY-B1480
    Ethoxzolamide
    		Inhibitor 99.85%
    Ethoxzolamide is a carbonic anhydrase inhibitor with Ki of 1 nM.
  • HY-402723
    hCAVII/IX-IN-1
    		Inhibitor
    hCAVII/IX-IN-1 (compound 4) is a hCAVII/IX inhibitor, with Ki values ​​of 56.5 nM and 38.2 nM, respectively. hCAVII/IX-IN-1 can be used in anticancer research.
  • HY-W012168
    4-Chloro-3-sulfamoylbenzoic acid
    		Inhibitor 99.79%
    4-Chloro-3-sulfamoylbenzoic acid is an inhibitor of human carbonic anhydrase, targeting the cytosolic isoforms hCA I and hCA II (glaucoma-associated), and the transmembrane isoforms hCA IV and hCA IX (tumor hypoxia-induced).
  • HY-B0122
    Topiramate
    		Inhibitor ≥98.0%
    Topiramate (McN 4853) is a broad-spectrum antiepileptic agent. Topiramate is a GluR5 receptor antagonist. Topiramate produces its antiepileptic effects through enhancement of GABAergic activity, inhibition of kainate/AMPA receptors, inhibition of voltage-sensitive sodium and calcium channels, increases in potassium conductance, and inhibition of carbonic anhydrase.
  • HY-N0639
    Punicalin
    		Inhibitor 99.89%
    Punicalin is a species that can be isolated from the leaves of Punica granatum. Punicalin is an active molecule against hepatitis b virus (HBV). Punicalin can induce pyroptosis. Punicalin is a Carbonic anhydrase inhibitor. Punicalin blocks the binding of S-glycoprotein and ACE2 receptors. Pnuicalin has anti-inflammatory, antioxidant and antiviral activity.
  • HY-P99023
    Girentuximab
    		Inhibitor 99.90%
    Girentuximab (G250) is a chimeric monoclonal antibody that binds carbonic anhydrase IX (CAIX), a cell surface glycoprotein ubiquitously expressed in clear cell renal cell carcinoma (ccRCC).
  • HY-B0553
    Methazolamide
    		Inhibitor 99.41%
    Methazolamide (L584601) is a sulfonamide derivative used as a carbonic anhydrase inhibitor with a Ki of 14 nM for human carbonic anhydrase II. Methazolamide, an intraocular pressure-lowering agent, reduces intraocular pressure elevations associated with glaucoma and other ocular disorders.
  • HY-B0124
    Zonisamide
    		Inhibitor 99.85%
    Zonisamide (AD 810) is an orally active carbonic anhydrase inhibitor, with Kis of 35.2 and 20.6 nM for hCA II and hCA V, respectively. Zonisamide exerts neuroprotective effects through anti-apoptosis and upregulating MnSOD levels. Zonisamide also increases the expression of Hrd1, thereby improving cardiac function in AAC rats. Zonisamide can be used in studies of seizure, parkinson’s disease and cardiac hypertrophy.
  • HY-B0283
    Acipimox
    		Inhibitor 99.86%
    Acipimox (K-9321), a nicotinic acid analogue, is an antilipolytic compound. Acipimox stimulates leptin releas, inhibits lipolysis and suppresses systemic levels of free fatty acids (FFAs) and improves insulin sensitivity.
  • HY-B0782A
    Acetazolamide sodium
    		Inhibitor 99.54%
    Acetazolamide sodium is a carbonic anhydrase (CA) IX inhibitor with an IC50 of 30 nM for hCA IX. Acetazolamide sodium has diuretic, antihypertensive and anti-gonococcal activities.
  • HY-B1424
    Benzthiazide
    		Inhibitor 99.70%
    Benzthiazide is a long-acting diuretic and a hypertension agent. Benzthiazide is an inhibitor of carbonic anhydrase 9 (CA9), with Kis of 8.0, 8.8 and 10 nM for CA9, CA2 and CA1, respectively. Benzthiazide also suppresses proliferation of cancer cells.
  • HY-B0109A
    Dorzolamide hydrochloride
    		Inhibitor 99.92%
    Dorzolamide (L671152) hydrochloride is a potent carbonic anhydrase II inhibitor, with IC50 values of 0.18 nM and 600 nM for red blood cell CA-II and CA-I respectively. Dorzolamide possesses anti-tumor activity.
  • HY-B0588
    Brinzolamide
    		Inhibitor 99.61%
    Brinzolamide (AL-4862) is a selective carbonic anhydrase II inhibitor with anIC50 value of 3.2 nM. Brinzolamide hydrochloride reduces intraocular pressure (IOP) by inhibiting ciliary CA-II and decreasing atrial fluid secretion. Brinzolamide can be used in glaucoma disease research.
  • HY-110243
    CAIX Inhibitor S4
    		Inhibitor 99.04%
    CAIX Inhibitor S4 is a potent and selective inhibitor of carbonic anhydrase IX/XII (CA IX/XII), with a Ki of 7 nM and 2 nM, respectively. CAIX Inhibitor S4 also inhibits CA II and CA I (Ki=546 and 5600 nM, respectively). CAIX Inhibitor S4 can inhibit the number of lung metastasis in orthotopic MDA-MB-231 mouse model without affecting primary tumor growth.
  • HY-76938
    Actarit
    		Inhibitor 99.58%
    Actarit, an orally active antirheumatic compound, has the potential to treat type II collagen-induced arthritis.
  • HY-118467
    Benzolamide
    		Inhibitor 99.07%
    Benzolamide (CL11366) is a potent carbonic anhydrase (CA) inhibitor, with Kis of 15 nM, 9 nM, 94 nM and 78 nM for hCA I, hCA II, EcoCAγ and VchCAγ, respectively. Benzolamide also inhibits CAS3, with a Ki of 54 nM. Benzolamide can be used for the research of glaucoma and seizures.
  • HY-B0397
    Dichlorphenamide
    		Inhibitor 98.90%
    Dichlorphenamide (Diclofenamide) is an orally active, specific, carbonic anhydrase inhibitor. Dichlorphenamide can reduce intraocular pressure by inhibiting the secretion of water from the eye. Dichlorphenamide can be used for glaucoma research.